About us

Energenesis is pleased to announce that our independently developed diabetic foot ulcer drug, ENERGI-F703DFU Gel, has been awarded the Excellence Award in the "Innovative Technology Award - Pharmaceutical and Applied Biotechnology Category" at the 2024 Taipei Biotech Awards.

ENERGI-F703DFU is an innovative small-molecule drug. Its unique ENERGI molecules can enter cells, elevate ATP energy levels, thereby accelerating cell migration and promoting wound healing. The application of this cutting-edge technology is expected to significantly improve the treatment outcomes for diabetic foot ulcers. Currently, ENERGI-F703DFU is undergoing Phase III clinical trials in both the United States and Taiwan, marking a crucial step towards commercialization.

This prestigious award recognition affirms our innovative achievements in the biotechnology and medical fields. We sincerely thank all our team members for their contributions, our partners for their support, and our investors for their trust. Energenesis will continue to uphold the spirit of innovation, striving to provide patients with superior medical solutions.